Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITATION: Neoadjuvant Durvalumab + Tremelimumab in CCA
NCT06341764Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in cholangiocarcinoma (CCA), sponsored by National Cancer Institute. Started Sep 2023; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06341764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341764.